136 related articles for article (PubMed ID: 38615584)
1. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
5. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
Yeo BSY; Song HJJMD; Soong YL; Chua MLK; Ang MK; Lim DWT; See A; Lim CM
Oral Oncol; 2023 Jan; 136():106242. PubMed ID: 36413976
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
Wang S; Chen S; Zhong Q; Liu Y
J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
[TBL] [Abstract][Full Text] [Related]
10. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
12. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S; Pedrazzoli P; Basso S; Bossi P; Bianco A; Imarisio I; Pagani A; De Cicco M; Muscianisi S; Casanova M; Morosi C; Bergamini C; Benazzo M; Cossu Rocca M; Perotti C; Baldanti F; Zecca M; Licitra LF; Comoli P
Front Immunol; 2023; 14():1208475. PubMed ID: 37497213
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
[TBL] [Abstract][Full Text] [Related]
15. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
Lee AZE; Tan LSY; Lim CM
Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
19. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]